Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Busulfan, Melphalan, and Bortezomib Conditioning for ASCT in Multiple Myeloma
NCT01605032Phase 2Completed
- Sponsor
- Albert Einstein College of Medicine
- Start
- Feb 2012
- Primary completion
- Mar 2018
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of busulfan, melphalan, bortezomib in multiple myeloma (MM), sponsored by Albert Einstein College of Medicine. Started Feb 2012; status: completed.
02
Drugs
busulfanmelphalanbortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01605032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01605032.